Liraglutide
Liraglutide (GLP-1 Receptor Agonist)
The first GLP-1 receptor agonist approved for weight management (Saxenda). A daily injectable that established the GLP-1 class as a major weight loss intervention.
Mechanism of Action
Liraglutide mimics GLP-1, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. 97% homology to human GLP-1 with a 13-hour half-life.
Health Claims & Evidence
Clinically significant weight loss
Reduces cardiovascular risk
Improves glycemic control
Short-Term Effects
Reduced appetite, nausea during dose escalation, gradual weight loss.
Long-Term Effects
Sustained weight loss and metabolic improvements.
Side Effects
Nausea, vomiting, diarrhea, constipation. Rare: pancreatitis, gallbladder disease.
Contraindications
Contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Liraglutide and weight management
Pi-Sunyer et al. · New England Journal of Medicine · 2015
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Liraglutide and related peptides, and prepare an educational research summary.
Explore Research